Neural Networks in Generalized Epilepsy and Novel Antiepileptic Drugs

Author(s): Felix-Martin Werner*, Rafael Coveñas*.

Journal Name: Current Pharmaceutical Design

Volume 25 , Issue 4 , 2019

Become EABM
Become Reviewer

Abstract:

Background: In previous works, alterations of neurotransmitters and neuropeptides in the brain areas involved in generalized epilepsy have been reported.

Objective: We reviewed the alterations of these neurotransmitters and neuropeptides in the following brain areas involved in generalized epilepsy: hippocampus, hypothalamus, thalamus and cerebral cortex. In these brain areas, the neural networks are also actualized. The mechanisms of action of newer antiepileptic drugs in the treatment of generalized epilepsy are also discussed.

Results: Up-dating the neurotransmitter and neuropeptide alterations, we found that hippocampal GABAergic neurons presynaptically inhibit epileptogenic neurons via GABAB receptors. Epilepsy modulating neuropeptides (galanin, neuropeptide Y, dynorphin) are also involved. GABA deficiency, serotonin hyperactivity, dopamine hyperactivity and glutamate excitotoxicity can enhance ictogenesis: neurons containing these neurotransmitters form the main neural circuit. An increased excitability occurs when the alteration of these neurotransmitters is permanent.

Conclusion: In preclinical studies, the GABAB receptor agonist GS 39,783 exerted a good antiepileptic effect. Perampanel, an AMPA receptor antagonist, showed good clinical effects in the treatment of partial-onset seizures and primary generalized tonic-clonic seizures. In this treatment, perampanel can be combined with other antiepileptic drugs. Brivaracetam, which shows a high affinity for the synaptic vesicle 2A, exerted a good efficacy in the treatment of adult focal seizures and secondarily generalized tonic-clonic seizures.

Keywords: Antiepileptic drug, brivaracetam, dopamine, GABAB receptor agonist, generalized epilepsy, glutamate, neurotransmitter imbalance, perampanel.

[1]
Werner FM, Coveñas R. Influence of GABAergic neurons and other neurotransmitters and neuropeptides on ictogenesis in generalized epilepsy. Ref Mod Neurosci Behav Psycho 2017; pp. 1-6.
[2]
Werner FM, Coveñas R. Classical neurotransmitters and neuropeptides involved in generalized epilepsy: A focus on antiepileptic drugs. Curr Med Chem 2011; 18(32): 4933-48.
[3]
Moseley BD, Sperling MR, Asadi-Pooya AA, et al. Efficacy, safety, and tolerability of adjunctive brivaracetam for secondarily generalized tonic-clonic seizures: Pooled results from three Phase III studies. Epilepsy Res 2016; 127: 179-85.
[4]
De Liso P, Vigevano F, Specchio N, et al. Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies-an Italian observational multicenter study. Epilepsy Res 2016; 127: 93-100.
[5]
Haug KH, Myhrer T, Fonnum F. The combination of donepezil and procyclidine protects against soman-induced seizures in rats. Toxicol Appl Pharmacol 2007; 220(2): 156-63.
[6]
Jeong JH, Choi BY, Kho AR, et al. Diverse effects of an acetylcholinesterase inhibitor, donepezil, on hippocampal neuronal death after pilocarpine-induced seizure. Int J Mol Sci 2017; 18(11): 2311.
[7]
Werner FM, Coveñas R. Classical neurotransmitters and neuropeptides involved in generalized epilepsy in a multi-neurotransmitter system: How to improve the antiepileptic effect? Epilepsy Behav 2017; 71(Pt B): 124-9
[8]
Lee CC, Chou IC, Tsai CH, et al. Association of idiopathic generalized epilepsy with polymorphisms in the neuronal nicotinic acetylcholine receptor subunits. J Clin Lab Anal 2007; 21(2): 67-70.
[9]
Ciumas C, Wahlin TB, Espino C, Savic I. The dopamine system in idiopathic generalized epilepsies: Identification of syndrome-related changes. Neuroimage 2010; 51(2): 606-15.
[10]
Houser CR. Plasticity and reorganization of GABA neurons in epilepsy 2009. 619-25
[11]
Lang M, Moradi-Chameh H, Zahid T, et al. Regulating hippocampal hyperexcitability through GABAB Receptors. Physiol Rep 2014; 2(4): e00278.
[12]
Tang FR, Chen PM, Tang YC, Tsai MC, Lee WL. Two-methyl-6-phenylethynyl-pyridine (MPEP), a metabotropic glutamate receptor 5 antagonist, with low doses of MK801 and diazepam: A novel approach for controlling status epilepticus. Neuropharmacology 2007; 53(7): 821-31.
[13]
Patsalos PN, Gougoulaki M, Sander JW. Perampanel serum concentrations in adults with epilepsy: effect of dose, age, sex, and concomitant antiepileptic drugs. Ther Drug Monit 2016; 38(3): 358-64.
[14]
De Sarro G, Russo E, Citraro R, Meldrum BS. Genetically epilepsy- prone rats (GEPRs) and DBA/2 mice: Two animal models of audiogenic reflex epilepsy for the evaluation of new generation AEDs. Epilepsy Behav 2017; 71(Pt B): 165-73
[15]
Loacker S, Sayyah M, Wittmann W, Herzog H, Schwarzer C. Endogenous dynorphin in epileptogenesis and epilepsy: Anticonvulsant net effect via kappa opioid receptors. Brain 2007; 130(Pt 4): 1017-28.
[16]
Lerner JT, Sankar R, Mazarati AM. Galanin and epilepsy. Cell Mol Life Sci 2008; 65(12): 1864-71.
[17]
Werner F-M, Coveñas R. Klassische Neurotransmitter und Therapiemöglichkeitenbei generalisierten Epilepsien 2009. 63
[18]
Garamendi-Ruiz I, García-García ME, Bertol-Alegre V, et al. One-year clinical experience of perampanel in Spain: A multicentre study of efficacy and tolerability. Epileptic Disord 2016; 18(2): 173-80.
[19]
Klein P, Diaz A, Gasalla T, Whitesides J. A review of the pharmacology and clinical efficacy of brivaracetam. Clin Pharmacol 2018; 10: 1-22.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 25
ISSUE: 4
Year: 2019
Page: [396 - 400]
Pages: 5
DOI: 10.2174/1381612825666190319121505
Price: $65

Article Metrics

PDF: 37
HTML: 10